Cargando…

Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials

STUDY OBJECTIVE: Telavancin and vancomycin are both approved for treatment of hospital‐acquired and ventilator‐associated bacterial pneumonias caused by Staphylococcus aureus, and both agents can cause renal dysfunction. The objective of this study was to assess renal function changes by performing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nogid, Boris, Lacy, Melinda K., Jacobs, Micah, Bruss, Jon, Dwyer, Jamie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221095/ https://www.ncbi.nlm.nih.gov/pubmed/30003567 http://dx.doi.org/10.1002/phar.2165

Ejemplares similares

Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies
por: Wilson, Samuel E., et al.
Publicado: (2017)

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles, et al.
Publicado: (2017)

2364. Evaluation of Renal Function Changes in Patients With Prolonged Telavancin Therapy (>21 Days): Results From the Telavancin Observational Use Registry (TOUR™)
por: Hassoun, Ali, et al.
Publicado: (2018)

Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2009)

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
por: Rubinstein, Ethan, et al.
Publicado: (2011)

Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles R., et al.
Publicado: (2021)

Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Reilly, Joseph, et al.
Publicado: (2020)

2369. Clinical Experience With Telavancin for Treatment of Patients With Monomicrobial S. aureus Infections (Vancomycin MIC ≥1 μg/mL) From TOUR™
por: Jacobs, Micah, et al.
Publicado: (2018)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

1323. Efficacy and Safety of Telavancin Compared to Vancomycin for Cystic Fibrosis Pulmonary Exacerbation in Adults
por: Shorman, Mahmoud, et al.
Publicado: (2021)

Efficacy of telavancin for treatment of surgical site infections
por: Wilson, SE, et al.
Publicado: (2008)

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Bressler, Adam M., et al.
Publicado: (2019)

2404. Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement
por: Bishop, Aaron, et al.
Publicado: (2018)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

Chemical Stability of Telavancin in Elastomeric Pumps()
por: Sand, Patrick, et al.
Publicado: (2015)

Role of telavancin in treatment of skin and skin structure infections
por: Bonkowski, Joseph, et al.
Publicado: (2010)

Update on the emerging role of telavancin in hospital-acquired infections
por: Nnedu, Obinna N, et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides
por: al Jalali, Valentin, et al.
Publicado: (2018)

Recurrence of skin infections in patients treated with telavancin versus vancomycin for complicated skin and soft tissue infections in a New Orleans emergency department
por: Dunbar, L, et al.
Publicado: (2008)

Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
por: Hooper, Candace Y, et al.
Publicado: (2012)

No Outbreak of Vancomycin and Linezolid Resistance in Staphylococcal Pneumonia over a 10-Year Period
por: Yayan, Josef, et al.
Publicado: (2015)

Attainment of therapeutic vancomycin level within the first 24 h
por: Honore, Patrick M., et al.
Publicado: (2019)

Target Attainment and Clinical Efficacy for Vancomycin in Neonates: Systematic Review
por: Mejías-Trueba, Marta, et al.
Publicado: (2021)

Evaluation of telavancin dose capping in a large community hospital
por: Hassoun, Ali, et al.
Publicado: (2017)

Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia
por: Rubinstein, Ethan, et al.
Publicado: (2014)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Attainment of therapeutic vancomycin level within the first 24 h: Authors' response
por: Baptista, João Pedro, et al.
Publicado: (2019)

Evaluation of Real-World Vancomycin Dosing and Attainment of Therapeutic Drug Monitoring Targets
por: Bradley, Nicole, et al.
Publicado: (2023)

Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections
por: Jafari Saraf, Lida, et al.
Publicado: (2011)

Efficacy and Safety of Telavancin in Clinical Trials: A Systematic Review and Meta-Analysis
por: Polyzos, Konstantinos A., et al.
Publicado: (2012)

Post-reconstitution Stability of Telavancin with Commonly Used Diluents and Intravenous Infusion Solutions
por: Gu, Zhengtian, et al.
Publicado: (2015)

The Role of the Staphylococcal VraTSR Regulatory System on Vancomycin Resistance and vanA Operon Expression in Vancomycin-Resistant Staphylococcus aureus
por: Qureshi, Nadia K., et al.
Publicado: (2014)

Epidemiology and Prognosis of Coagulase-Negative Staphylococcal Endocarditis: Impact of Vancomycin Minimum Inhibitory Concentration
por: García de la Mària, Cristina, et al.
Publicado: (2015)

Staphylococcal Pneumonia
por: Grant, A. P., et al.
Publicado: (1954)

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)
por: Dunbar, Lala M, et al.
Publicado: (2008)

291 Efficacy and safety of telavancin in the treatment ofram-positive bloodstream infections in cancer patients
por: Chaftari, Anne-Marie, et al.
Publicado: (2014)

Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment
por: Wu, Wanhong, et al.
Publicado: (2021)

Population Pharmacokinetic Analysis Proves Superiority of Continuous Infusion in PK/PD Target Attainment with Oxacillin in Staphylococcal Infections
por: Murínová, Irena, et al.
Publicado: (2022)

Protocol for a randomised controlled trial of continuous infusions of vancomycin to improve the attainment of target vancomycin levels in young infants: The VANC trial
por: Gwee, Amanda, et al.
Publicado: (2018)

Activity of daptomycin- and vancomycin-loaded poly-epsilon-caprolactone microparticles against mature staphylococcal biofilms
por: Ferreira, Inês Santos, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cshg4epskcc055lrcf61sb600d